Literature DB >> 15200439

Chronic kidney disease: the distribution of health care dollars.

Wendy L St Peter1, Samina S Khan, James P Ebben, Brian J G Pereira, Allan J Collins.   

Abstract

BACKGROUND: The cost of care for end-stage renal disease (ESRD) is known to be high. The factors responsible for higher ESRD cost develop during chronic kidney disease (CKD), where the data on distribution of cost are limited.
METHODS: This retrospective cohort study of 1995 through 1998 incident dialysis patients was performed to study the distribution of costs during the 24 months prior to initiation of dialysis. Patient data were obtained from the Centers for Medicare and Medicaid Services (CMS). Patients who were Medicare eligible for at least 2 years prior to initiation of dialysis were included in the study. Financial data were obtained from Medicare Part A and Part B claims and inflationary adjustments were made. The study period was divided into four segments based on overall distribution of cost.
RESULTS: The mean age was 75 years, 51% were males, 73% were white, and 22% were black. Overall, patient comorbidity increased significantly during the study years. Cost showed a sharp increase in the last 6 months prior to initiation of dialysis. Hospitalization was the major component of cost throughout study period. Patients who initiated hemodialysis incurred a higher cost compared to patients who initiated other modes of kidney replacement therapy. Patients with diabetes or cardiovascular disease incurred higher cost compared to those who had no diabetes or cardiovascular disease, respectively.
CONCLUSION: These data showed that hospitalization was the major component of the sharp increase in cost around the initiation of dialysis. Increased comorbidity was associated with higher cost. A focus on timely management of CKD may prevent future morbidity and costs.

Entities:  

Mesh:

Year:  2004        PMID: 15200439     DOI: 10.1111/j.1523-1755.2004.00733.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  22 in total

1.  Renal function and healthcare costs in patients with polycystic kidney disease.

Authors:  Krista L Lentine; Huiling Xiao; Gerardo Machnicki; Adrian Gheorghian; Mark A Schnitzler
Journal:  Clin J Am Soc Nephrol       Date:  2010-06-10       Impact factor: 8.237

2.  Mortality and Recovery Associated with Kidney Failure due to Acute Kidney Injury.

Authors:  Silvi Shah; Anthony C Leonard; Kathleen Harrison; Karthikeyan Meganathan; Annette L Christianson; Charuhas V Thakar
Journal:  Clin J Am Soc Nephrol       Date:  2020-06-17       Impact factor: 8.237

Review 3.  Renal protection in hypertensive patients: selection of antihypertensive therapy.

Authors:  René R Wenzel
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Healthcare costs of the progression of chronic kidney disease and different dialysis techniques estimated through administrative database analysis.

Authors:  Alessandro Roggeri; Daniela Paola Roggeri; Carlo Zocchetti; Maurizio Bersani; Ferruccio Conte
Journal:  J Nephrol       Date:  2016-05-10       Impact factor: 3.902

5.  Addressing Financial Disincentives to Improve CKD Care.

Authors:  Jeffrey S Berns; Tonya L Saffer; Eugene Lin
Journal:  J Am Soc Nephrol       Date:  2018-10-10       Impact factor: 10.121

6.  Pharmaceutical cost distribution in childhood chronic kidney disease.

Authors:  Janis M Dionne; Kelvin Lou; Lee Er; Kathleen Collin; Colin T White
Journal:  Pediatr Nephrol       Date:  2012-05-01       Impact factor: 3.714

7.  Hospitalization Risk among Older Adults with Chronic Kidney Disease.

Authors:  Eugenia Wong; Shoshana H Ballew; Natalie Daya; Junichi Ishigami; Casey M Rebholz; Kunihiro Matsushita; Morgan E Grams; Josef Coresh
Journal:  Am J Nephrol       Date:  2019-07-16       Impact factor: 3.754

8.  Added value of screening for CKD among the elderly or persons with low socioeconomic status.

Authors:  Priya Vart; Sjimen A Reijneveld; Ute Bültmann; Ronald T Gansevoort
Journal:  Clin J Am Soc Nephrol       Date:  2015-03-16       Impact factor: 8.237

9.  Economic burden of chronic kidney disease in Korea using national sample cohort.

Authors:  Seon-Ha Kim; Min-Woo Jo; Dun-Sol Go; Dong-Ryeol Ryu; Jongha Park
Journal:  J Nephrol       Date:  2017-03-16       Impact factor: 3.902

10.  Effect of Apabetalone on Cardiovascular Events in Diabetes, CKD, and Recent Acute Coronary Syndrome: Results from the BETonMACE Randomized Controlled Trial.

Authors:  Kamyar Kalantar-Zadeh; Gregory G Schwartz; Stephen J Nicholls; Kevin A Buhr; Henry N Ginsberg; Jan O Johansson; Ewelina Kulikowski; Kenneth Lebioda; Peter P Toth; Norman Wong; Michael Sweeney; Kausik K Ray
Journal:  Clin J Am Soc Nephrol       Date:  2021-04-27       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.